The liver is the readout, but the damage is body-wide. Fat in liver cells is the visible edge of insulin resistance, and that metabolic state drives the rest: adults with MASLD run a 45% higher risk of heart attack and cardiovascular death, independent of cholesterol, blood pressure, and BMI 1, and more than double the risk of type 2 diabetes 2.
Most people with fatty liver are fine; a small minority are not. The line between them is scarring. People whose liver shows full cirrhosis have roughly four times the death rate of people with no scarring at all 3. The heart is what kills most of them; cirrhosis is the rarer end.
The whole point is one cheap calculation. It sorts who needs a closer, costlier look from who can just recheck later.
If FIB-4 is low or indeterminate, the treatment is weight loss. Losing 7% of body weight resolves the liver inflammation in most people; losing 10% reverses actual scarring in 45% of them 5. A Mediterranean pattern and two or three coffees a day both help 6 7; alcohol accelerates the scarring, so cut it. Confirmed moderate-to-advanced scarring now has two approved drugs, resmetirom and weekly semaglutide, both prescribed on top of the weight-loss work 8 9.
Early MASLD reverses β as a biopsy finding, not a slogan.
- Weeks: insulin sensitivity improves before the scale moves; liver enzymes start dropping by the second or third month 6.
- Months: hold 7β10% weight loss and inflammation clears, scarring regresses, and the cardiometabolic risk bends back toward baseline 5.
- Years: the drift back is the real enemy. If lifestyle won't hold and FIB-4 said you were in trouble, the drugs pick up the fibrosis work.
The fine print β when to skip it, and what people get wrong
"My enzymes are normal, so I'm fine." A third of patients with advanced scarring have ALT in the normal range 10; FIB-4 closes the question, a normal ALT doesn't. "Only obese people get it." Roughly 10β20% of cases have a normal BMI, driven by visceral fat and genes like PNPLA3 6.
The drugs are prescription-only. Resmetirom is out in decompensated cirrhosis and pregnancy; the GLP-1 medications are out in personal or family history of medullary thyroid cancer or MEN2 8.
- 1Mantovani A, Csermely A, Petracca G, et al. (2021). Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. link
- 2Mantovani A, Petracca G, Beatrice G, et al. (2022). Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. link
- 3Ng CH, Lim WH, Hui Lim GE, et al. (2023). Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. link
- 4Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. (2023). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. link
- 5Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. link
- 6EASL, EASD, EASO (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. link
- 7Kennedy OJ, Roderick P, Buchanan R, et al. (2024). Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis. Nutrients. link
- 8Harrison SA, Bedossa P, Guy CD, et al. (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). New England Journal of Medicine. link
- 9Sanyal AJ, Newsome PN, Kliers I, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). New England Journal of Medicine. link
- 10Marjot T, Thompson A, Cole A, et al. (2024). Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT. Annals of Hepatology. link
Related in the handbook (15)
- β If you're carrying fatty liver, trading sugary drinks for diet versions lowers liver fat β better still, switch to water.
- β Berberine is a third-tier option for fatty liver: modest reductions in liver fat, nowhere near a substitute for weight loss or the main drugs.
- β Coffee is one of the few things shown to lower liver-scarring risk in fatty liver disease β a couple of cups a day quietly works in your favour here.
- β When diet alone won't shift fatty liver, GLP-1 drugs drive the weight loss that reverses it β and cut the heart risk that rides along.
- β For the subset whose fatty liver has progressed to scarring, resmetirom is the first approved drug that can bend the trajectory.
- β Eating in an earlier, shorter window is one of the cheaper ways to start unloading a fatty liver.
- β For some people with advanced fatty liver, high-dose vitamin E is an evidence-backed, clinician-supervised option.
- β The diet that builds fatty liver is heavy on ultra-processed food and fructose; cutting it back is the core of the fix.
- β Alcohol drives fatty liver too, and it compounds the metabolic kind β worth knowing which fight your liver is in.
- β Fatty liver tracks the fat wrapped around your organs, and a DEXA scan quantifies exactly that, often before the liver shows up on any other test.
- β Fatty liver pushes ferritin up, which is why a high ferritin doesn't always mean iron overload β read it alongside TSAT.
- β Before blaming fat alone for a struggling liver, iron-overload hemochromatosis is the other common cause worth ruling out.
- β A genuinely more permeable gut is one documented feature of fatty liver β the real version of 'leaky gut,' not the supplement-aisle one.
- β The same insulin resistance behind PCOS drives fatty liver β worth checking even if you feel fine.
- β Fatty liver roughly doubles your odds of type 2 diabetes β they're two faces of the same metabolic problem.